Historical Stock Chart
1 Year : From May 2012 to May 2013
LONDON-- Pharmaceutical and healthcare company GlaxoSmithKline PLC (GSK.LN) Thursday said the United States Food and Drug Administration, or FDA, has approved Horizant (gabapentin enacarbil) Extended-Release Tablets for the management of postherpetic neuralgia (PHN) in adults.
-Horizant was discovered and is being developed by XenoPort Inc. (XNPT).
-Efficacy and safety of Horizant for the management of PHN was evaluated in a single 12-week principal efficacy trial, plus two supportive studies that all met their respective primary endpoints.
-Three clinical studies involved 574 adult patients from the U.S., Canada and Germany.
-Recommended dosage for the management of PHN in adults is 600 mg, or milligram, twice daily.
-XenoPort is entitled to a milestone payment of $10 million from GlaxoSmithKline following the first commercial sale of the product after approval for PHN.
-Shares of GlaxoSmithKline at 1037 GMT up 13 pence, or 1%, at 1439.5 pence.
-Write to Tapan Panchal at firstname.lastname@example.org